{"id":"W2468099764","doi":"10.1212/wnl.86.16_supplement.s49.008","title":"Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.008)","year":2016,"lang":"en","type":"article","venue":"Neurology","topic":"vaccines and immunoinformatics approaches","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Montreal Neurological Institute and Hospital","funders":"","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Double blind; Opera; Interferon beta-1a; Relapsing remitting; Interferon beta; Dermatology; Internal medicine; Art; Alternative medicine; Art history; Psychiatry; Placebo; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004441336,0.0002360049,0.0007420729,0.00009630289,0.0001003935,0.000009253409,0.0002259312,0.0001473755,0.000004489082],"category_scores_gemma":[0.00007781141,0.0001076155,0.0001583341,0.0002185147,0.0002794059,0.00001612312,0.0003483958,0.0001285362,1.849826e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000142537,"about_ca_system_score_gemma":0.00001707881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003107941,"about_ca_topic_score_gemma":0.00008870138,"domain_scores_codex":[0.9984714,0.0002385862,0.0005651039,0.000354921,0.000148278,0.0002216857],"domain_scores_gemma":[0.9988905,0.0001146365,0.0003161615,0.0005380729,0.0001062687,0.0000344094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5680594,0.001322938,0.3593813,0.0001153347,0.001803586,4.53358e-7,0.0005492226,0.0004684391,0.05188468,0.00001802846,0.00001997417,0.01637668],"study_design_scores_gemma":[0.5209206,0.0750449,0.1386468,0.0003883954,0.001723763,0.000003155877,0.00008777266,0.001721587,0.2608446,0.000003754881,0.0001087773,0.0005059032],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979931,0.000398196,0.00001763687,0.000288383,0.00008455646,0.001172425,0.00001518586,0.000004836924,0.00002565598],"genre_scores_gemma":[0.999637,0.0001193819,0.00001798719,0.00005166797,0.00001366657,0.0001100613,0.00002559747,0.00001439703,0.00001021285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2207345,"threshold_uncertainty_score":0.4388434,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02517918105396329,"score_gpt":0.2884214249727736,"score_spread":0.2632422439188103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}